ImmunoTargets and Therapy
Q2 Journal
Open Access
Journal
Country
New Zealand
Pacific Region
Subject Area and Category
Immunology and Microbiology
└
Immunology
Q2
└
Immunology and Allergy
Q2
Publisher
SJR 2025
1.110
Q2
SJR Score
H-Index
36
Citations / Doc (2yr)
3.94
Total Docs. (latest)
91
Total Citations (3yr)
324
Publication type
Journals
ISSN
22531556
Coverage
2015-2026
Journal Rank
#4,114
Subject Categories
Immunology
Q2
Immunology and Allergy
Q2
Subject Areas
Aims & Scope
ImmunoTargets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management.
Basic immunology and physiology of the immune system in health, and disease will be also covered.
In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.
This journal explores the evidence behind new and existing therapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional.
As of 1st April 2019, ImmunoTargets and Therapy will no longer consider meta-analyses for publication.
Abstracting & Indexing
Scopus
Google Scholar
Directory of Open Access Journals (DOAJ)
Web of Science
Embase
Detailed Metrics
| Total Docs. (latest) | 91 |
| Total Docs. (3 years) | 76 |
| Total Refs. | 7,436 |
| Total Citations (3 years) | 324 |
| Citable Docs. (3 years) | 74 |
| Citations / Doc. (2 years) | 3.94 |
| Ref. / Doc. | 81.71 |
| % Female | 47.4% |
Metrics Visualization
Latest year data vs 3-year cumulative figures
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Researcher Reviews
Write a ReviewNo reviews yet for this journal.
Be the first to share your experience!
Share Your Experience
Your review will be published after moderation. Email will not be displayed publicly.